{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116364","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.198978+00:00","generated_at":"2026-06-08T06:03:56.703745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Marker Therapeutics reports Q3 net loss $3.0M; complete response in first MT-601 lymphoma patient","bullets":["Net loss of $3.0M for Q3 2023 vs $6.9M in Q3 2022; R&D expenses down to $2.0M from $3.6M.","First lymphoma patient treated with MT-601 in Phase 1 APOLLO trial achieved complete metabolic response after failing CAR T therapy.","MT-401 (zedenoleucel) received Orphan Drug Designation from EMA for AML; clinical trial for MT-401 off-the-shelf expected in 2024.","Cash and cash equivalents of $17.5M as of September 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116364","json":"https://secwatch.observer/filing/0001104659-23-116364.json","markdown":"https://secwatch.observer/filing/0001104659-23-116364.md","text":"https://secwatch.observer/filing/0001104659-23-116364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923116364/0001104659-23-116364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923116364/tm2330322d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:03:56.703745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb43b2fda7798d8903d5f3e64594c5e7b464631b","claim":"Marker Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income ($3.0) million.","evidence_excerpt":"Marker reported a net loss of ($3.0) million for the quarter ended September 30, 2023, compared to a net loss of ($6.9) million, inclusive of the $(1.2) million loss from discontinued operations, reflected in the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923116364/0001104659-23-116364-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"($3.0) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}